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Available online 9 October 2013Conversion of cell fate is not only an essential biological ques-
tion, but also has great clinical values. In early 1950s, cellular
reprogramming was ﬁrst achieved using the technique of so-
matic cell nuclear transfer (SCNT), which transferred the nu-
clear of somatic cells into an enucleated oocyte, thus
converted the mature somatic cells into pluripotent state.
Using this technique, Xenopus laevis and the famous sheep
‘‘Dolly’’ were cloned successfully in 1960s and 1990s, respec-
tively. Following that, many other species have been cloned
via the SCNT technique, and the mechanisms underlying cellu-
lar reprogramming have been extensively studied.
After SCNT, another breakthrough in cell fate conversion
was achieved in 2006, with the Japanese scientist Yamanaka
and his colleagues demonstrated that mouse ﬁbroblasts could
be reprogrammed into pluripotent state by exogenous expres-
sion of four transcriptional factors, Oct4, Sox2, Klf4 and
c-Myc. Those induced pluripotent stem (iPS) cells have equiv-
alent properties to embryonic stem (ES) cells, which can go
indeﬁnite self-renewal and can differentiate into various cell
types of three germ layers both in vitro and in vivo. Subse-
quently, human iPS cells were also generated successfully,
which were considered to have great clinical application poten-
tial for their promise to overcome the ethic and immune-rejec-
tion obstacles faced by ES cells. The recently established
patient and disease-speciﬁc iPS cells have also opened new* Corresponding author.
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Since 2006, iPS cells have become one of the most attrac-
tive and competitive ﬁelds in life science research, many
important progresses have been made during the past few
years. Besides the early stage retrovirus transfection method
for exogenous gene expression, various new approaches have
been demonstrated to generate iPS cells successfully, includ-
ing using non-integrative vectors, mRNAs or chemicals.
These new methods have the potential to reduce the tumori-
genesis risk of iPS cells by avoiding the genomic mutations
caused by retroviruses, although the pluripotency of iPS cells
produced by some of these methods still need to be further
conﬁrmed.
The immunogenicity of iPS cells is still a controversial issue.
It was reported that iPS cells are immunogenic post transplan-
tation, which may be caused by mutations during the repro-
gramming and long time in vitro culture process. However,
there were also controversial reports about non-immunogenic
iPS cells. It is critical to prevent or reduce the potential immu-
nogenicity of human iPS cells post transplantation before
applying them in clinical therapies.
Using approaches similar to the iPS technique, scientists
have been able to convert one type of differentiated somatic
cells into another type, without going through the pluripotent
stage. This technique, named trans-differentiation, is consid-
ered to be less tumorigenic than the iPS approach, as the
resulting cells are non-pluripotent. Nevertheless, how to pre-
cisely control the fate of reprogrammed cells to generate well
differentiated and functional cells is a major task for all cell
reprogramming techniques. And the therapeutic effects of
either human iPS cells or their derivatives still need to be
carefully investigated before some clinical trials could be
launched.cademy of Sciences and Genetics Society of China. Production and hosting
258 Zhou Q / iPS Cells: Current Progress and Future PerspectivesTo introduce the recent progresses in cellular reprogram-
ming, especially in the iPS cell research ﬁeld, we have produced
this special issue on iPS cell studies and related issues. We
apologize for works or aspects not being covered here due to
page limitations.Acknowledgements
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